This functionality is implemented using Javascript. It cannot work without it, etc...

Estamos cargando la información...

Saltar al contenido

Políticas Médicas

Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.

Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.

ID Título Última Revisión Siguiente Revisión Descripción Acceso
P1.001.009 Elahere (mirvetuximab soravtansine-gynx) Sep 17, 2024 Sep 20, 2025 Elahere is a folate receptor alpha (frα)-directed antibody and microtubule inhibitor conjugate... Ver
P1.001.010 Ublituximab-xiiy (Briumvi) Sep 22, 2025 Sep 20, 2026 Briumvi (ublituximab-xiiy) is a cd20-directed monoclonal antibody indicated for the treatment of adults with... Ver
P1.001.011 Imjudo (tremelimumab-actl) injection Sep 22, 2025 Sep 20, 2026 Imjudo (tremelimumab-actl) is a cytotoxic t-lymphocyte–associated antigen 4 (ctla-4) blocking antibody... Ver
P1.001.012 Teclistamab (Tecvayli) Sep 22, 2025 Sep 20, 2026 Teclistamab (tecvayli) is a bispecific b-cell maturation antigen (bcma)-directed cd3 t-cell engaging antibody... Ver
P1.001.013 Enjaymo Sep 22, 2025 Sep 20, 2026 Sutimlimab-jome (enjaymo) is a monoclonal antibody that inhibits the classical complement pathway by binding... Ver
P1.001.014 Opdualag Sep 22, 2025 Sep 20, 2026 Opdualag (nivolumab + relatlimab-rmbw) is a fixed-dose combination of two immune checkpoint inhibitors:... Ver
P1.001.015 Xenpozyme Sep 22, 2025 Sep 20, 2026 Xenpozyme® (olipudase alfa-rpcp) is an enzyme replacement therapy (ert) for the treatment of non-cns... Ver
P1.001.016 Fyarro Sep 22, 2025 Sep 20, 2026 Fyarro™ (nab-sirolimus) is an mtor inhibitor formulated as sirolimus protein-bound particles... Ver
P1.002.001 Vedolizumab Dec 16, 2024 Dec 20, 2024 Vedolizumab is a recombinant human igg1 monoclonal antibody produced in chinese hamster ovaries. it binds to... Ver
P1.002.002 Benralizumab Dec 17, 2024 Dec 20, 2025 Benralizumab is an interleukin-5 antagonist monoclonal antibody (igg1 kappa) for the add-on maintenance... Ver
P1.002.003 Somatuline® Depot; Lanreotide Dec 17, 2024 Dec 20, 2025 Somatuline® depot; lanreotide is used to treat people with acromegaly (condition in which the body... Ver
P1.002.004 Nucala® (mepolizumab) Dec 17, 2024 Dec 20, 2025 Mepolizumab is an interleukin-5 antagonist monoclonal antibody (igg1 kappa) for the add-on maintenance... Ver
P1.002.005 Ocrevus™ (ocrelizumab) Dec 17, 2024 Dec 20, 2025 Ocrelizumab is a humanized monoclonal antibody that is directed against cd20-expressing b-cells. cd20 is a... Ver
P1.002.006 Simponi ARIA® (golimumab) Dec 17, 2024 Dec 20, 2025 Golimumab is in a class of drugs called biologics. golimumab is a treatment for adults with moderate to... Ver
P1.002.007 Stelara® (ustekinumab) Dec 17, 2024 Dec 20, 2025 Stelara is a human igg1κ monoclonal antibody that binds with high affinity and specificity to the p40... Ver
P1.002.008 Tysabri® (natalizumab) Dec 17, 2024 Dec 20, 2025 Tysabri® (natalizumab) is a monoclonal antibody produced with recombinant dna technology in murine... Ver
P1.002.009 Xolair® (omalizumab) Dec 17, 2024 Dec 20, 2025 Omalizumab is an anti-ige monoclonal antibody produced by recombinant dna technology using chinese hamster... Ver
P1.002.010 Ruconest (C1 Esterase Inhibitor [recombinant]) Sep 22, 2025 Sep 20, 2026 Ruconest is a recombinant c1 esterase inhibitor indicated for the treatment of acute attacks of hereditary... Ver
P1.002.011 Ultomiris® (ravulizumab-cwvz) Jun 23, 2025 Jun 20, 2026 Ravulizumab-cwvz is a complement inhibitor indicated as a treatment for adult patients, 18 years and older,... Ver
P1.002.012 Soliris (eculizumab) Sep 22, 2025 Sep 20, 2026 Soliris is a complement inhibitor indicated for the treatment of patients with paroxysmal nocturnal... Ver
787-277-6653 787-474-6326